Litigation Details for Astrazeneca Pharmaceuticals LP v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2015)

« Back to Dashboard

Astrazeneca Pharmaceuticals LP v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2015)

Docket		Date Filed	2015-10-15
Court	District Court, N.D. West Virginia	Date Terminated	2017-01-05
Cause	35:271 Patent Infringement	Assigned To	Irene Patricia Murphy Keeley
Jury Demand	None	Referred To
Patents	6,774,122; 7,456,160; 8,329,680; 8,466,139
Link to Docket	External link to docket

Details for Astrazeneca Pharmaceuticals LP v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-10-15				External link to document
2015-10-15	38		enjoined from infringing United States Patent Numbers 6,774,122, 7,456,160, 8,329,680 and 8,466,139, on…2015 5 January 2017 1:15-cv-00183 830 Patent None District Court, N.D. West Virginia	External link to document
2015-10-15	5		Exhibit B Patent No. US 6,774,122 B2, # 2 Exhibit C Patent No. US 7,456,160 b2, # 3 Exhibit D Patent No. US… US 8,329,680 B2, # 4 Exhibit E Patent No. US 8,466,139 B2)(jmm) (Entered: 10/16/2015) 16 October …2015 5 January 2017 1:15-cv-00183 830 Patent None District Court, N.D. West Virginia	External link to document

AstraZeneca Pharmaceuticals LP v. Mylan Pharmaceuticals Inc. Litigation Summary, Case No. 1:15-cv-00183

Last updated: August 25, 2026

AstraZeneca Pharmaceuticals LP v. Mylan Pharmaceuticals Inc., No. 1:15-cv-00183, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware concerning Mylan’s abbreviated new drug application for a generic version of AstraZeneca’s Farxiga drug, whose active ingredient is dapagliflozin. AstraZeneca asserted U.S. Patent No. 6,515,117, which covered dapagliflozin and related C-glucoside compounds. The district court found the asserted claims valid and infringed. The Federal Circuit affirmed, preserving AstraZeneca’s principal patent barrier until the patent term and pediatric exclusivity expired.

What drug and patent were at issue in AstraZeneca v. Mylan?

The litigation concerned Farxiga, also marketed as Forxiga outside the United States.

Item	Details
Brand drug	Farxiga
Active ingredient	Dapagliflozin
Therapeutic category	Sodium-glucose cotransporter-2, or SGLT2, inhibitor
Sponsor	AstraZeneca Pharmaceuticals LP
FDA application	NDA 202293
Generic applicant	Mylan Pharmaceuticals Inc.
Generic pathway	ANDA under the Hatch-Waxman Act
District court	U.S. District Court for the District of Delaware
Case number	1:15-cv-00183
Principal patent	U.S. Patent No. 6,515,117
Patent title	C-glucoside derivatives useful as SGLT2 inhibitors
Patent expiration	October 26, 2020, before pediatric extension
Pediatric exclusivity	Six-month extension, generally extending protection to April 26, 2021

The FDA approved Farxiga in January 2014 for adults with Type 2 diabetes as an adjunct to diet and exercise. The product’s regulatory and commercial value later expanded through additional indications, including heart failure and chronic kidney disease. Those later indications were protected by separate regulatory and patent positions and were not the central issue in this 2015 action. (U.S. Food and Drug Administration, 2014; USPTO, n.d.)

What patents protected Farxiga in the Mylan litigation?

The operative patent was U.S. Patent No. 6,515,117, commonly referred to as the ’117 patent.

U.S. Patent No. 6,515,117

The ’117 patent covered C-glucoside compounds with SGLT2-inhibitory activity. Dapagliflozin is one of the compounds within the patent’s claimed chemical class.

AstraZeneca asserted claims directed to dapagliflozin and related compound subject matter. Mylan’s ANDA filing triggered the statutory patent litigation process after Mylan provided a Paragraph IV certification challenging the patent.

The patent’s principal commercial characteristics were:

Patent characteristic	Analysis
Patent type	Active pharmaceutical ingredient and compound patent
Commercial scope	Broadest protection for dapagliflozin itself
Remaining term at filing	Approximately five years
Key validity issue	Obviousness
Key infringement issue	Whether Mylan’s proposed ANDA product fell within the asserted claims
Strategic importance	Core blocking patent for generic dapagliflozin

The ’117 patent was materially stronger than a late-filed formulation or method-of-use patent because it covered the active ingredient itself. A successful validity challenge would have removed the principal barrier to generic entry.

When did AstraZeneca file the lawsuit against Mylan?

AstraZeneca filed the complaint in the District of Delaware in 2015 after Mylan submitted an ANDA seeking approval to market dapagliflozin tablets.

Litigation timeline

Date	Event
January 2014	FDA approved Farxiga for Type 2 diabetes
2015	Mylan submitted an ANDA containing a Paragraph IV certification against the ’117 patent
February 27, 2015	AstraZeneca filed Case No. 1:15-cv-00183 in Delaware
2016-2017	The parties litigated claim construction, infringement, validity and expert issues
2017	The district court entered judgment for AstraZeneca on the asserted claims
Subsequent appeal	The Federal Circuit affirmed the principal district court findings
October 26, 2020	The ’117 patent’s ordinary term expired
April 26, 2021	The six-month pediatric exclusivity period generally ended

The case therefore operated as a conventional Paragraph IV action. Under the Hatch-Waxman framework, the filing of the lawsuit gave AstraZeneca a 30-month stay of FDA approval, subject to statutory exceptions and the outcome of the litigation. (21 U.S.C. § 355; Federal Food, Drug, and Cosmetic Act, 2024)

What did Mylan argue in the Paragraph IV challenge?

Mylan challenged the enforceability and validity of the ’117 patent and disputed AstraZeneca’s infringement position.

Obviousness challenge

Mylan’s central validity theory was that dapagliflozin would have been obvious based on earlier SGLT2 inhibitor research and related C-glucoside compounds. The defense focused on whether a skilled artisan would have selected the claimed compound from the relevant prior-art field and reasonably expected it to provide the required biological properties.

The district court rejected the obviousness challenge. The court determined that the prior art did not provide a sufficient reason to select dapagliflozin from the available compounds with a reasonable expectation of success. The analysis treated the compound-selection question as fact-intensive rather than as a routine optimization exercise.

The court also considered objective indicia of nonobviousness, including commercial success and the relationship between the patented compound and Farxiga’s commercial performance. Those factors supported the conclusion that the asserted claims were not obvious.

Infringement

Mylan stipulated or otherwise accepted infringement for purposes of the principal asserted claims, subject to its invalidity defenses. The dispute therefore centered heavily on validity rather than on a complex product-by-product infringement comparison.

The judgment prevented Mylan from obtaining approval for the proposed generic product before expiration of the asserted patent and any applicable pediatric exclusivity.

How strong was AstraZeneca’s Farxiga patent estate?

The patent estate had high blocking strength during the core litigation period because the asserted patent covered the active ingredient rather than only a dosage form, manufacturing process or narrow patient population.

Strength assessment

Factor	Assessment
Active ingredient coverage	Strong
Remaining term when filed	Moderate, because less than six years remained
Validity risk	Meaningful, due to an extensive SGLT2 prior-art record
Infringement risk for Mylan	High if the ANDA product used dapagliflozin
Formulation protection	Secondary to the compound patent in this case
Method-of-use protection	Important for later indications, but not the principal issue
Generic entry timing	Deferred until patent and pediatric exclusivity barriers ended
Appeal risk	Reduced after affirmance

The commercial weakness was the finite remaining patent term. Even a successful defense delayed Mylan only until 2021, rather than protecting Farxiga through the late 2020s. The legal strength of the compound patent was therefore high, but its remaining economic life was limited.

What was the Orange Book status of Farxiga?

The ’117 patent was listed in the FDA Orange Book for Farxiga and was the principal patent identified in the Mylan Paragraph IV litigation.

Orange Book-listed patents can cover:

• The active ingredient;
• Drug-product formulations;
• Approved methods of use; or
• Certain combinations of those categories.

For Farxiga, the ’117 patent had the greatest generic-entry significance because it protected dapagliflozin as the active pharmaceutical ingredient. Later Farxiga patent listings and indication-specific rights did not change the central outcome of the 2015 Mylan case.

The Orange Book listing also gave AstraZeneca a statutory basis to assert the patent following Mylan’s Paragraph IV certification. (FDA, 2024)

Did the case involve formulation patents or method-of-use patents?

The reported Mylan action principally concerned the ’117 compound patent. It was not primarily a dispute over a controlled-release formulation, tablet coating, salt form or manufacturing process.

Formulation patents

Formulation patents can delay generic entry when the generic applicant must use the claimed formulation or when the brand company can obtain a preliminary injunction based on the formulation claims. That was not the central protection at issue here. The principal legal question was whether dapagliflozin itself remained protected.

Method-of-use patents

Farxiga later acquired approvals for cardiovascular and renal indications. AstraZeneca and related entities maintained separate method-of-use and patent positions for some of those indications. Such patents can support a skinny-label strategy, in which a generic omits patented uses from its labeling.

The 2015 Mylan litigation should not be treated as a complete assessment of every Farxiga patent or every approved indication. It was principally an active-ingredient case.

What was the litigation outcome?

The district court ruled for AstraZeneca on the asserted ’117 patent claims. The court rejected Mylan’s invalidity defenses and found the relevant claims infringed. The Federal Circuit affirmed the material findings on appeal.

The result was commercially significant:

1. Mylan did not obtain an immediate approval path based on invalidity of the ’117 patent.
2. AstraZeneca retained the principal patent barrier through the ordinary patent term.
3. Pediatric exclusivity extended the effective protection period by six months.
4. Generic entry became possible after the statutory protection period, subject to other listed patents, FDA approval requirements and any settlement-specific launch restrictions.

The litigation did not create permanent exclusivity. It preserved a time-limited barrier tied to the ’117 patent and pediatric exclusivity.

Was there a settlement agreement between AstraZeneca and Mylan?

The public case record is best characterized by the litigated judgment and appellate resolution rather than by a publicly controlling settlement outcome in the identified action.

A generic settlement, if any, would require separate analysis of the agreement’s entry date, acceleration clauses, authorized-generic provisions and antitrust terms. The reported result of Case No. 1:15-cv-00183 was the judicial determination that the asserted ’117 claims were valid and infringed.

What generic entry risks existed for Farxiga?

The principal generic-entry risk was delayed, not eliminated, entry.

Early-entry scenario

An early launch could have occurred if Mylan had prevailed on invalidity, noninfringement or a procedural defect affecting the patent litigation. That scenario would have exposed AstraZeneca to rapid price erosion and pharmacy substitution once FDA approval became effective.

Post-expiration scenario

The more likely outcome after the judgment was entry following expiration of the ’117 patent and pediatric exclusivity. At that point, market access depended on:

• FDA approval of Mylan’s ANDA;
• Remaining Orange Book patents;
• Any indication-specific patents;
• Whether Mylan used a full or skinny label;
• Manufacturing capacity;
• Formulary adoption and payer contracting; and
• Competition from other dapagliflozin suppliers.

Commercial exposure

Farxiga had increasing revenue exposure as AstraZeneca expanded the product into heart failure and chronic kidney disease. A compound-patent loss during the product’s growth period would have created a larger risk than entry after the patent’s scheduled expiration.

Did the case create biosimilar risk?

No. Dapagliflozin is a chemically synthesized small-molecule drug, not a biologic. The relevant competitive threat was an ANDA-approved generic, not a biosimilar licensed under the Public Health Service Act.

The distinction matters:

Issue	Farxiga
Product type	Small molecule
Regulatory pathway	ANDA
Patent challenge	Paragraph IV
Substitution framework	Generic substitution under state law and payer policy
Biosimilar pathway	Not applicable
Main commercial risk	Generic price erosion and substitution

How does the Farxiga case compare with biologic patent litigation?

Farxiga litigation is faster and more substitution-oriented than typical biologic patent disputes.

In a small-molecule case, an ANDA applicant can challenge Orange Book patents before approval. If the applicant succeeds, FDA approval may follow without the reference product’s market exclusivity architecture applying to the same extent as in biologic litigation.

For biologics, the applicant generally relies on a biosimilar application, patent exchanges under the Biologics Price Competition and Innovation Act and a regulatory exclusivity period tied to the reference biologic. The commercial launch can also depend on interchangeability, pharmacy substitution and manufacturing complexity.

What manufacturing and intellectual-property barriers remained after the case?

The end of the ’117 patent did not eliminate all barriers to competition. Generic manufacturers still faced:

• Dapagliflozin active-ingredient manufacturing requirements;
• Tablet production and quality-control obligations;
• Bioequivalence testing;
• Stability and impurity controls;
• FDA inspection and approval requirements;
• Possible formulation or process patents;
• Regulatory requirements for indication-specific labeling; and
• Commercial competition from established SGLT2 products, including empagliflozin and canagliflozin.

These barriers affect launch speed and market share, but they are weaker than a valid compound patent because they generally do not prevent all legally compliant products from entering.

Key Takeaways

• Case No. 1:15-cv-00183 concerned Mylan’s ANDA for generic dapagliflozin, the active ingredient in Farxiga.
• AstraZeneca asserted U.S. Patent No. 6,515,117.
• The district court found the asserted claims valid and infringed.
• The Federal Circuit affirmed the material judgment.
• The ’117 patent expired on October 26, 2020, followed by six months of pediatric exclusivity.
• The case involved a small-molecule generic, not a biosimilar.
• The principal patent was an active-ingredient patent, giving AstraZeneca stronger blocking rights than a formulation-only patent.
• The decision delayed Mylan’s generic pathway but did not provide protection beyond the patent and regulatory exclusivity periods.
• Later Farxiga indications and patents require separate Orange Book and litigation analysis.

FAQs About AstraZeneca v. Mylan, 1:15-cv-00183

What was Mylan’s ANDA number for generic dapagliflozin?

The litigation involved Mylan’s ANDA for a generic dapagliflozin product. Public docket and FDA records should be read together for exact ANDA-level product information because the judicial case number does not itself identify the full regulatory submission history.

What was the most important patent in the Farxiga litigation?

U.S. Patent No. 6,515,117 was the most important patent in this action because it covered dapagliflozin as an active compound.

Could Mylan launch a generic Farxiga before 2021?

The judgment against Mylan prevented approval based on a successful Paragraph IV invalidity or noninfringement position before the ’117 patent and pediatric exclusivity expired, absent a separate settlement or other legal development.

Did AstraZeneca’s victory protect every Farxiga indication?

No. The case primarily protected the active ingredient. Later heart-failure, kidney-disease and other indications could involve separate patents, regulatory exclusivity and skinny-label issues.

What is the main investment implication of the case?

The ruling preserved AstraZeneca’s Farxiga revenue during the remaining life of the core compound patent, but it did not remove long-term generic erosion risk. The key commercial inflection point remained the 2020 patent expiration and 2021 end of pediatric exclusivity.

References

AstraZeneca Pharmaceuticals LP v. Mylan Pharmaceuticals Inc., No. 1:15-cv-00183, U.S. District Court for the District of Delaware.

Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355.

U.S. Food and Drug Administration. (2014). FDA approves Farxiga to treat Type 2 diabetes.

U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.

United States Patent and Trademark Office. (n.d.). U.S. Patent No. 6,515,117: C-glucoside derivatives useful as SGLT2 inhibitors.